CU6
CLARITY PHARMA ORDINARYClarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
CU6
CU6
CLARITY PHARMA ORDINARY
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceutical products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 28 Aug | — | — |
| 27 Aug | — | — |
| 26 Aug | — | — |
| 25 Aug | 8.24% | — |
| 24 Aug | 8.25% | — |
| 21 Aug | 8.29% | — |
| 20 Aug | 8.10% | — |
| 19 Aug | 8.35% | — |
| 18 Aug | 8.36% | — |
| 17 Aug | 8.29% | — |
| 14 Aug | 8.31% | — |
| 13 Aug | 8.23% | — |
Clarity Pharma (CU6) Short Interest Summary
Clarity Pharma (CU6) currently has 8.24% of its shares sold short (30.8 million shares, worth approximately $77.2 million), based on ASIC short position data reported on 25 August 2026 (T+4 reporting lag). That makes CU6 the #28 most shorted stock on the ASX most shorted list. Short interest in CU6 is down 0.11% over the past week and down 0.30% over the past month. CU6 is part of the Health Care sector on the ASX.
Recent CU6 Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 25 Aug 2026 | 8.24% | 30.8M | $2.48 |
| 24 Aug 2026 | 8.25% | 30.8M | $2.39 |
| 21 Aug 2026 | 8.29% | 30.9M | $2.48 |
| 20 Aug 2026 | 8.10% | 30.2M | $2.62 |
| 19 Aug 2026 | 8.35% | 31.2M | $2.49 |
| 18 Aug 2026 | 8.36% | 31.2M | $2.57 |
| 17 Aug 2026 | 8.29% | 30.9M | $2.59 |
| 14 Aug 2026 | 8.31% | 31.0M | $2.63 |
| 13 Aug 2026 | 8.23% | 30.7M | $2.80 |
| 12 Aug 2026 | 8.26% | 30.8M | $2.81 |
CU6 Short Selling — Frequently Asked Questions
What is Clarity Pharma (CU6)'s current short interest?
Clarity Pharma (CU6) currently has a short interest of 8.24% of total shares outstanding. This means 8.24% of CU6's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is CU6 heavily shorted on the ASX?
CU6 has a moderate level of short interest at 8.24%. While below the heavily shorted threshold of 10%, this indicates notable bearish positioning. CU6 is currently ranked #28 among the most shorted stocks on the ASX.
What does short interest mean for CU6 investors?
Short interest in CU6 shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 8.24%, CU6's short interest is at a moderate level. See our short squeeze candidates and days to cover analysis for more context.
Where does this CU6 short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for CU6.